Table 3. Neurological manifestations and laboratory findings in patients with laboratory-confirmed MERS.
| Patient 1 | Patient 2 | Patient 3 | Patient 4 | |
|---|---|---|---|---|
| Neurological symptoms | Hypersomnolence and weakness in all four limbs | Tingling/pain in both hands and below the knees, and weakness in both legs | Tingling in distal parts of both hands and feet | Tingling in both hands |
| Days after MERS onset | Unclear* | 16 | 20 | 21 |
| Neurological examination | ||||
| Cranial nerves | Ptosis and ophthalmoplegia | Normal | Normal | Normal |
| Motor | Weakness in all four limbs | Proximal dominant weakness in both legs | Normal | Normal |
| Sensory | Normal | Normal | Hypesthesia in distal parts of all four limbs | Normal |
| Deep tendon reflex | Hyporeflexia in all four limbs | Hyporeflexia in both legs | Hyporeflexia in both legs | Normal |
| Cerebellar function | Limb ataxia | Normal | Normal | Normal |
| Laboratory findings | ||||
| CSF | Normal | NA | NA | NA |
| NCS | Normal | Normal | Normal | NA |
| Peak serum creatine kinase, U/L | 45 | 48 | 99 | NA |
*Neurological symptoms were detected 24 days after the initial onset of respiratory symptoms.
CSF: cerebrospinal fluid, MERS: Middle East respiratory syndrome, NA: not available, NCS: nerve conduction study.